FUNDAMENTALS · Fundamentals · US Healthcare

Halozyme Therapeutics (HALO) Fundamentals 2026 — P/E 26.9x, Revenue Analysis | SniperIQ

Halozyme Therapeutics (HALO) is a US-listed Healthcare company in Biotechnology with a market capitalization of $9.3B, trading at $78.56 on the NASDAQ. This SniperIQ fundamentals page covers Halozyme Therapeutics's valuation (P/E 26.9x, P/B 42.3x), profitability (net margin 23.1%), revenue (

.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$9.3B
P/E (TTM)26.9x
Net Margin23.1%
Revenue (FY25)
.4B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Halozyme Therapeutics's market cap?

Halozyme Therapeutics (HALO) has a market capitalization of approximately $9.3B, trading at $78.56 on the NASDAQ. Market cap moves with the live share price.

What is Halozyme Therapeutics's P/E ratio?

Halozyme Therapeutics's trailing twelve-month P/E ratio is 26.9x, with a price-to-book (P/B) of 42.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Halozyme Therapeutics?

Halozyme Therapeutics runs a net profit margin of 23.1%, a gross margin of 76.9%, and an operating margin of 57.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Halozyme Therapeutics generate?

Halozyme Therapeutics reported revenue of

.4B for fiscal year 2025, with net income of
17M and earnings per share (EPS) of 2.64. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Halozyme Therapeutics pay a dividend?

Halozyme Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Halozyme Therapeutics financially healthy?

Halozyme Therapeutics carries a debt-to-equity ratio of 9.76x and a current ratio of 2.76x, with a market beta of 0.84. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Halozyme Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Halozyme Therapeutics (HALO) the key facts are: market cap $9.3B, P/E 26.9x, revenue

.4B, 52-week range 57.33-82.26. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Halozyme Therapeutics's full fundamentals live

Get Halozyme Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.